Kinase activity of mutant LRRK2 mediates neuronal toxicity

被引：510

作者：

Smith, Wanli W.

Pei, Zhong

Jiang, Haibing

Dawson, Valina L.

Dawson, Ted M.

Ross, Christopher A.

机构：

[1] Johns Hopkins Univ, Sch Med, Dept Psychiat, Div Neurobiol, Baltimore, MD 21287 USA

[2] Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21287 USA

[3] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21287 USA

[4] Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21287 USA

[5] Johns Hopkins Univ, Sch Med, Inst Cell Engn, Baltimore, MD 21287 USA

[6] Johns Hopkins Univ, Sch Med, Program Cellular & Mol Med, Baltimore, MD 21287 USA

来源：

NATURE NEUROSCIENCE | 2006年 / 9卷 / 10期

关键词：

D O I：

10.1038/nn1776

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

Mutations in the the leucine-rich repeat kinase-2 (LRRK2) gene cause autosomal- dominant Parkinson disease and some cases of sporadic Parkinson disease. Here we found that LRRK2 kinase activity was regulated by GTP via the intrinsic GTPase Roc domain, and alterations of LRRK2 protein that reduced kinase activity of mutant LRRK2 correspondingly reduced neuronal toxicity. These data elucidate the pathogenesis of LRRK2-linked Parkinson disease, potentially illuminate mechanisms of sporadic Parkinson disease and suggest therapeutic targets.

引用

页码：1231 / 1233

页数：3

共 15 条

[1] LRRK2 mutations and Parkinsonism
Albrecht, M
[J]. LANCET, 2005, 365 (9466) : 1230 - 1230
[2] Roc, a Ras/GTPase domain in complex proteins
Bosgraaf, L
Van Haastert, PJM
[J]. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2003, 1643 (1-3): : 5 - 10
[3] Di Fonzo A, 2005, LANCET, V365, P412
[4] LRRK2 mutations in Parkinson disease
Farrer, M
Stone, J
Mata, IF
Lincoln, S
Kachergus, J
Hulihan, M
Strain, KJ
Maraganore, DM
[J]. NEUROLOGY, 2005, 65 (05) : 738 - 740
[5] Genetics of Parkinson's disease
Gasser, T
[J]. CURRENT OPINION IN NEUROLOGY, 2005, 18 (04) : 363 - 369
[6] Common LRRK2 mutation in idiopathic Parkinson's disease
Gilks, WP
Abou-Sleiman, PM
Gandhi, S
Jain, S
Singleton, A
Lees, AJ
Shaw, K
Bhatia, KP
Bonifati, V
Quinn, NP
Lynch, J
Healy, DG
Holton, JL
Revesz, T
Wood, NW
[J]. LANCET, 2005, 365 (9457) : 415 - 416
[7] The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity
Gloeckner, CJ
Kinkl, N
Schumacher, A
Braun, RJ
O'Neill, E
Meitinger, T
Kolch, W
Prokisch, H
Ueffing, M
[J]. HUMAN MOLECULAR GENETICS, 2006, 15 (02) : 223 - 232
[8] Kinase activity is required for the toxic effects of mutant LRRK2/dardarin
Greggio, Elisa
Jain, Shushant
Kingsbury, Ann
Bandopadhyay, Rina
Lewis, Patrick
Kaganovich, Alice
van der Brug, Marcel P.
Beilina, Alexandra
Blackinton, Jeff
Thomas, Kelly Jean
Ahmad, Rill
Miller, David W.
Kesavapany, Sashi
Singleton, Andrew
Lees, Andrew
Harvey, Robert J.
Harvey, Kirsten
Cookson, Mark R.
[J]. NEUROBIOLOGY OF DISEASE, 2006, 23 (02) : 329 - 341
[9] LRRK1 protein kinase activity is stimulated upon binding of GTP to its Roc domain
Korr, D
Toschi, L
Donner, P
Pohlenz, HD
Kreft, B
Weiss, B
[J]. CELLULAR SIGNALLING, 2006, 18 (06) : 910 - 920
[10] Genetics of Parkinson's disease
Morris, HR
[J]. ANNALS OF MEDICINE, 2005, 37 (02) : 86 - 96

← 1 2 →